El Paso, TX, (Uptick Newswire – August 1, 2016) — Premier Biomedical, Inc. (OTCQB: BIEI), a biotech research public company, and Advanced Technologies Solutions (ATS), a leader in natural ingredient pain relief compounds and delivery technologies, announced the signing of a Letter of Intent (LOI) to form a Joint Venture (JV) to manufacture and distribute products to treat neuropathic and other localized pain. The formation of this joint venture is expected to expedite the development of a series of topical and oral opioid-free pain treatments to compete in the $40 billion pain management segment of the U.S. healthcare market.
William A. Hartman, President and CEO of Premier Biomedical, stated: “We are very excited about this joint venture. The technology and skills that ATS brings to this partnership will accelerate our efforts to bring opioid-free pain management products to the market, as early as 2017. This is the first in a series of joint ventures which we are pursuing to bring effective treatments to the greatest number of patients in the shortest possible timeframe.”
Ron LaBorde, Owner and Founder of Advanced Technologies Solutions, added, “With the synergy of a professional business entity, and the technologically advanced methods, for both topical and transdermal delivery of natural compounds that ATS brings to this venture, we expect to rapidly help reduce the abuse and side effects of conventional pain relief drugs.”
For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical Inc.
About Advanced Technologies Solutions
Advanced Technologies Solutions is a San Diego, California based company and a leader in transdermal patch technology for the administration of natural ingredient products to relieve localized and general pain , which has been a focal point for the owner and founder of the company. With 35 plus years of experience in science, engineering and medical diagnostics, ATS brings together aspects of design, natural product formulation, production and automation in the manufacture of pain management devices.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Source: Uptick Newswire